8-K
INTELLIGENT BIO SOLUTIONS INC. (INBS)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February7, 2025
INTELLIGENT
BIO SOLUTIONS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39825 | 82-1512711 |
|---|---|---|
| (State of<br><br> <br>Incorporation) | (Commission<br><br> <br>File<br> Number) | (IRS<br> employer<br><br> <br>identification<br> no.) |
135West, 41^st^ Street, 5thFloor
New
York, NY 10036
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (646)
828-8258
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, $0.01 par value | INBS | The<br> Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item7.01 Regulation FD Disclosure.
On February 7, 2025, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”) announcing that Avon Freight Group has selected the Company’s non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing across its three UK sites. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing disclosure is qualified in its entirety by the full text of the Press Release.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
Item9.01 Financial Statements and Exhibits.
| No. | Description |
|---|---|
| 99.1 | Press release dated February 7, 2025 |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:<br> February 7, 2025 | ||
|---|---|---|
| INTELLIGENT BIO SOLUTIONS INC. | ||
| By: | /s/ Spiro Sakiris | |
| Name: | Spiro<br> Sakiris | |
| Title: | Chief<br> Financial Officer |
Exhibit 99.1
Intelligent Bio SolutionsExpands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission
UK drug testing market projected to hit $453M by 2030, positioning INBS as a scalable, cost-effective industry leader
NEWYORK, February 07, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Avon Freight Group (“Avon”) has selected its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing across its three UK sites, supporting proactive risk management and employee well-being. The addition of Avon further expands INBS’ client network of over 400 accounts in 19 countries.
Avon is implementing in-house drug testing for the first time, seeking a more respectful and practical alternative to the costly and intrusive random oral swab testing previously carried out by external providers. Avon’s adoption of INBS’ less invasive, rapid, and hygienic fingerprint sweat-based drug testing supports its efforts to improve workplace safety while maintaining a positive work culture.
Martin Bullimore, Commercial & Procurement Contracts Manager at Avon Freight Group, commented, “We’ve never had an in-housetesting solution before, and moving to fingerprint drug testing is a big step forward for us. We recognized the need for a more proactiveapproach to workplace testing and appreciated the non-invasive nature of this solution. The system allows us to conduct random testingwithout disrupting operations or imposing on our employees’ personal lives and reinforces our commitment to a safe, effective,and respectful workplace. The feedback has been extremely positive overall, with many stakeholders realizing its value.”
As more businesses in the logistics and transport sector recognize the limitations of traditional drug screening methods, solutions such as INBS’ Drug Screening System are increasingly becoming the preferred choice. Market research estimates the UK Drug of Abuse Testing Services Market to be the fastest-growing regional market in Europe^1^, projected to reach $453 million by 2030^2^. INBS is well-established and positioned to satisfy this growing demand with its scalable and cost-effective solution.
The Company expects further growth this year, following its U.S. FDA 510(k) submission in December 2024. Expansion into the U.S. presents significant opportunities for INBS and its innovative drug testing technology. The Company’s unique, non-invasive solution addresses the challenges faced by safety-sensitive industries, streamlines drug testing processes, and provides an alternative that supports employee well-being and compliance. By leveraging its expertise and proven success in the UK, INBS aims to establish a strong foothold in the U.S. market.
AboutAvon Freight Group
Founded in the 1970s, Avon Freight Group has built a reputation for excellent customer-focused service by adapting to the evolving needs of its clients. Avon delivers reliable and cost-effective freight, distribution, and warehousing solutions across the UK, Ireland, Europe, and beyond through continued growth and investment in its warehouse, modern vehicle fleet, and technology. The company’s dedicated, experienced team takes pride in exceeding expectations and working collaboratively with clients to achieve their goals.
For more information, visit: https://www.avonfreightgroup.co.uk
AboutIntelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release.
^1^Horizon Grand View Research. Europe Drug of Abuse Testing Services Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-of-abuse-testing-services-market/europe
^2^Horizon Grand View Research. UK Drug of Abuse Testing Services Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-of-abuse-testing-services-market/uk
Forward-LookingStatements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CompanyContact:
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor& Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
